Press Releases

- MAR 04 2014
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I/II Trial of Novel Anti-Cancer Drug ONC201
Hummelstown, PA (March 4, 2014) – Oncoceutics, Inc., a biotechnology company focused on developing innovative oncology treatments addressing major unmet medical needs to advance cancer care, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for the Phase I/II trial of ONC201, the lead drug compound

Read >
- DEC 09 2013
Data Presented at ASH Showing ONC201 Induces Apoptosis in Mantle Cell Lymphoma
Hummelstown, PA (December 9, 2013) – Oncoceutics, Inc. announced that a research team led by Michael Andreeff, MD, PhD, at the University of Texas MD Anderson Cancer Center, has presented data on ONC201, the lead drug compound developed by the company, at the annual meeting of the American Society of Hematology (ASH) in New Orleans.

Read >

- OCT 03 2013
Oncoceutics and Calvert Research Announce Investment Partnership to Advance ONC201 to an IND Filing
Hummelstown, PA (October 3, 2013) – Oncoceutics, Inc. announced the closing of an investment by Calvert Research, LLC into the company that will be used to advance ONC201 to an IND filing. Oncoceutics is developing ONC201, an orally active small molecule with a compelling efficacy and safety profile in preclinical studies against cancer cells (in

Read >
- JUN 24 2013
Kuwait University Medical School Professor Joins Scientific Advisory Board
Hummelstown, PA (June 24, 2013) – Oncoceutics, Inc. announced that Kuwait University Medical School Professor Fahd Al-Mulla has joined the company’s scientific advisory board. Dr. Al-Mulla FRCP is University Professor of molecular Pathology at Kuwait University Medical School and is the director of genomic medicine at Genatak, Kuwait. Prior to joining Genatak, Dr. Al-Mulla established

Read >

Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I/II Trial of Novel Anti-Cancer Drug ONC201